US Edition
Everest Medicines Unveils Breakthroughs in AI+mRNA Platform, Reinforces Global Leadership in Next-Gen mRNA Innovation
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.4 Articles
4 Articles
Hong Kong, July 4, 2025 – (Asia Pacific Business News via SeaPRwire.com) – Recently, Genting Everest (HKEX: 1952.
Hong Kong, July 4, 2025 – (Asia Pacific Business News via SeaPRwire.com) – Recently, Genting Everest (HKEX: 1952.
Everest Medicines Unveils Breakthroughs in AI+mRNA Platform, Reinforces Global Leadership in Next-Gen mRNA Innovation
HONG KONG, July 4, 2025 - (ACN Newswire) - Everest Medicines (HKEX: 1952.HK) recently unveiled major breakthroughs in its proprietary AI-powered mRNA platform during its 2025 R&D Day held in Shanghai. The event showcased the company's progress in building a fully integrated and independently operated mRNA platform and highlighted significant breakthroughs across several pipeline programs in cancer and autoimmune diseases. These achievements not …
Everest Medicines targets global expansion with proprietary, AI-driven mRNA platform
After years of building a robust commercial base through in-licensing, Hong Kong-listed biopharmaceutical firm Everest Medicines is entering a new phase of growth: one defined by a “dual-engine” strategy that blends in-house innovation with global partnerships and in-licensing. Central to this effort is its clinically validated mRNA (messenger ribonucleic acid) platform the company believes can rival the best in class. At Everest’s “mRNA Platfor…
Coverage Details
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
To view factuality data please Upgrade to Premium
